Trisha Dwight

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8111481/publications.pdf

Version: 2024-02-01

40 papers	2,026 citations	257101 24 h-index	315357 38 g-index
40 all docs	40 docs citations	40 times ranked	3035 citing authors

#	Article	IF	Citations
1	Involvement of the PAX8/Peroxisome Proliferator-Activated Receptor Î³ Rearrangement in Follicular Thyroid Tumors. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4440-4445.	1.8	204
2	Consensus Statement on next-generation-sequencing-based diagnostic testing of hereditary phaeochromocytomas and paragangliomas. Nature Reviews Endocrinology, 2017, 13, 233-247.	4.3	198
3	Assessing mutant p53 in primary high-grade serous ovarian cancer using immunohistochemistry and massively parallel sequencing. Scientific Reports, 2016, 6, 26191.	1.6	162
4	Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma. Scientific Reports, 2016, 6, 22477.	1.6	129
5	Loss of SDHA Expression Identifies SDHA Mutations in Succinate Dehydrogenaseâ€“deficient Gastrointestinal Stromal Tumors. American Journal of Surgical Pathology, 2013, 37, 226-233.	2.1	119
6	FamilialSDHAMutation Associated With Pituitary Adenoma and Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1103-E1108.	1.8	102
7	Fumarate Hydrataseâ€“deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings. American Journal of Surgical Pathology, 2016, 40, 599-607.	2.1	102
8	Silencing of thePTENtumor-suppressor gene in anaplastic thyroid cancer. Genes Chromosomes and Cancer, 2002, 35, 74-80.	1.5	94
9	Alternative Genetic Pathways in Parathyroid Tumorigenesis*. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3775-3780.	1.8	84
10	Succinate Dehydrogenase Deficiency Is Rare in Pituitary Adenomas. American Journal of Surgical Pathology, 2014, 38, 560-566.	2.1	71
11	Alternative Genetic Pathways in Parathyroid Tumorigenesis. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 3775-3780.	1.8	69
12	Expression profiling reveals a distinct transcription signature in follicular thyroid carcinomas with a PAX8-PPARÎ³ fusion oncogene. Oncogene, 2005, 24, 1467-1476.	2.6	68
13	Involvement of the MEN1 gene locus in familial isolated hyperparathyroidism. European Journal of Endocrinology, 2002, 147, 313-322.	1.9	48
14	TERT structural rearrangements in metastatic pheochromocytomas. Endocrine-Related Cancer, 2018, 25, 1-9.	1.6	45
15	A report of a national mutation testing service for the MEN1 gene: clinical presentations and implications for mutation testing. Journal of Medical Genetics, 2005, 42, 69-74.	1.5	44
16	Bayesian approach to determining penetrance of pathogenic SDH variants. Journal of Medical Genetics, 2018, 55, 729-734.	1.5	44
17	Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. Frontiers in Oncology, 2018, 8, 314.	1.3	43
18	Multiple Endocrine Tumors Associated with Germline MAX Mutations: Multiple Endocrine Neoplasia Type 5?. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1163-e1182.	1.8	43

#	Article	IF	Citations
19	Fine-structure deletion mapping of 10q22-24 identifies regions of loss of heterozygosity and suggests that sporadic follicular thyroid adenomas and follicular thyroid carcinomas develop along distinct neoplastic pathways. , 1999, 26, 322-328.		38
20	Independent Genetic Events Associated with the Development of Multiple Parathyroid Tumors in Patients with Primary Hyperparathyroidism. American Journal of Pathology, 2002, 161, 1299-1306.	1.9	36
21	Loss of heterozygosity in sporadic parathyroid tumours: involvement of chromosome 1 and the MEN1 gene locus in 11q13.. Clinical Endocrinology, 2000, 53, 85-92.	1.2	34
22	Overexpression of miR-210 is associated with SDH-related pheochromocytomas, paragangliomas, and gastrointestinal stromal tumours. Endocrine-Related Cancer, 2014, 21, 415-426.	1.6	34
23	Characteristic sequence motifs located at the genomic breakpoints of the translocation t(X;18) in synovial sarcomas. Oncogene, 2003, 22, 2215-2222.	2.6	31
24	Pheo-Type: A Diagnostic Gene-expression Assay for the Classification of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1034-1043.	1.8	29
25	Utility of the succinate:fumarate ratio for assessing SDH dysfunction in different tumor types. Molecular Genetics and Metabolism Reports, 2017, 10, 45-49.	0.4	26
26	Analysis of SDHAF3 in familial and sporadic pheochromocytoma and paraganglioma. BMC Cancer, 2017, 17, 497.	1.1	21
27	Treatment preferences in men with erectile dysfunction: an open label study in Korean men switching from sildenafil citrate to tadalafil. Asian Journal of Andrology, 2007, 9, 760-770.	0.8	17
28	Primary hyperparathyroidism as first manifestation in multiple endocrine neoplasia type 2A: an international multicenter study. Endocrine Connections, 2020, 9, 489-497.	0.8	17
29	A Rapid Method for DNA Extraction from Fine-Needle Aspiration Biopsies of Thyroid Tumors, and Subsequent RET Mutation Analysis. Cancer Detection and Prevention, 1998, 22, 544-548.	2.1	10
30	Cousins not twins: intratumoural and intertumoural heterogeneity in syndromic neuroendocrine tumours. Journal of Pathology, 2017, 242, 273-283.	2.1	9
31	Comprehensive analyses of somatic TP53 mutation in tumors with variable mutant allele frequency. Scientific Data, 2017, 4, 170120.	2.4	9
32	Metabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma. Hormone and Metabolic Research, 2019, 51, 443-450.	0.7	9
33	Effectiveness of antidepressants in the treatment of major depressive disorder in Latin America. International Journal of Psychiatry in Clinical Practice, 2007, 11, 129-139.	1.2	8
34	Genotype-Phenotype Features of Germline Variants of the TMEM127 Pheochromocytoma Susceptibility Gene: A 10-Year Update. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e350-e364.	1.8	8
35	Frequency of codon 1061 and codon 1309 APC mutations in Australian familial adenomatous polyposis patients. Human Mutation, 1998, 11, S56-S57.	1.1	7
36	Molecular cytogenetic characterization of primary cultures and established cell lines from non-medullary thyroid tumors. International Journal of Oncology, 2005, 26, 141.	1.4	6

#	Article	IF	Citations
37	Functional significance of germline EPAS1 variants. Endocrine-Related Cancer, 2021, 28, 97-109.	1.6	6
38	Parathyroid tumorigenesis in association with primary hyperparathyroidism. Current Opinion in Endocrinology, Diabetes and Obesity, 2002, 9, 51-60.	0.6	1
39	Impact of molecular cytogenetics on localization and identification of cancer-related genes in endocrine tumor development. Current Opinion in Endocrinology, Diabetes and Obesity, 2003, 10, 176-185.	0.6	1
40	Measuring Tumor Succinate and Fumarate to Resolve Pathogenicity of an SDHA Variant. Clinical Chemistry, 2021, 67, 696-699.	1.5	0